Liquidia (LQDA) Q2 2024 earnings summary

Executive summary

• Awaiting FDA decision on YUTREPIA for PAH and PH-ILD, with commercial teams ready for immediate launch upon approval; no legal barriers remain following recent court rulings favoring approval.

• Focused on therapies for rare cardiopulmonary diseases, with YUTREPIA as lead candidate and L606 in clinical development.

• Revenue primarily from Sandoz promotion agreement for generic treprostinil injection; YUTREPIA launch pending regulatory and litigation outcomes.

• Net loss for Q2 2024 was $27.9 million ($0.37 per share), compared to $23.5 million ($0.36 per share) in Q2 2023; six-month net loss was $68.9 million.

• Cash and cash equivalents were $133.1 million as of June 30, 2024, up from $83.7 million at year-end 2023.

Financial highlights

• Q2 2024 revenue was $3.7 million, down from $4.8 million in Q2 2023, mainly due to lower sales volumes.

• Cost of revenue increased to $1.5 million from $0.7 million year-over-year, driven by sales force expansion.

• Research and development expenses for Q2 2024 were $9.4 million, down from $17.7 million in Q2 2023, mainly due to a prior year $10 million license fee.

• General and administrative expenses rose to $20 million from $9.2 million, mainly due to higher personnel, commercial, and legal costs.

• Gross margin for Q2 2024 was 59.2%, down from 86.0% in Q2 2023, due to increased cost of revenue.

Outlook and guidance

• Confident in near-term approvability of YUTREPIA for both PAH and PH-ILD, with commercial team prepared for launch.

• ASCENT trial expected to complete by year-end, with data publication planned for 2025.

• Registrational global trial for L606 in PH-ILD patients planned to initiate by year-end.

• Company expects to require additional capital to fund operations and product development, with future funding needs dependent on YUTREPIA commercialization timing.

• Cash runway expected to support objectives, with flexibility to adjust spending if approval is delayed.